Our Community News A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis May 2021 British Skin Foundation eczema research A new British Skin Foundation-funded paper on model-based meta-analysis of recent clinical trials for nine biological eczema drugs has recently been published. Researcher Dr Reiko Tanaka from Imperial College London explains: "Eczema (atopic dermatitis) patients demonstrate variability in drug response to biologic drugs. We aimed to identify what causes the patients’ variability and to investigate whether there are alternative drug targets that may work better." Dr Reiko Tanaka We developed a mathematical model that describes systems-level eczema disease pathogenesis and the mode of action of the biologics. Computational simulation of the model identified simultaneous inhibition of IL-13 and IL-22 as a promising drug target for dupilumab poor responders. The model serves as a computational platform for model-informed drug development for precision medicine. What this research means for people with atopic dermatitis Investigation on new drugs can be accelerated by a computational method as shown in this study. The results of previously clinical trials were integrated together to develop a computer model that can be considered as “virtual people with AD”. Computer simulation using the virtual people helps to identify potential new drug targets. Donate to more research like this Read the paper here YouTube Video on the paper What is eczema? By donating to skin disease research you are helping us to find treatments and cures for common conditions like eczema, acne and psoriasis through to potential killers like melanoma skin cancer. Thank you.